Kusurinomadoguchi, Inc.

5592 株式会社くすりの窓口

Health Information Services · Growth

PRICE: ¥2,547 · MKT CAP: ¥28.6B · P/E: 13.8x · P/B: 3.38x · DIV YIELD: 1.1%

PRICE — 5Y

Characteristics & Business Summary

Kusurinomadoguchi, Inc. provides solutions for pharmacies and medical care in Japan. The company offers EPARK drug counter, a pharmacy/drugstore search and reservation site; matching site to buy and sell dead stock medicines at dispensing pharmacies; site for...

Income Statement Highlights (¥ Million, except EPS/DPS in ¥)

Fiscal Period	FY 2023	FY 2024
Net Sales	8,721	11,199
Operating Profit	1,370	1,954
Ordinary Profit	1,326	1,940
Net Profit	871	2,035
EPS	¥79	¥181
DPS	¥0	¥27

Balance Sheet & Valuation Highlights

Total Assets ¥12B

Net Assets (Equity) ¥9B

Equity Ratio 69.5%

ROE (Return on Equity) 24.1%

Cash & Equivalents ¥2B

Interest-Bearing Debt ¥0B

Capital Expenditure (CapEx) ¥0B

Depreciation & Amort. ¥1B

Major Shareholders

1. NBSEヘルステック投資事業有限責任組合 28.0%
2. 株式会社EPARK 27.9%
3. SBIイノベーションファンド１号 16.1%
4. Nomura Trust and Banking Co., Ltd. 3.5%
5. 木下圭一郎 1.9%
6. 堤幸治 1.6%
7. Hikari Tsushin, Inc. 1.4%
8. Ueda Yagi Tanshi Co., Ltd. 1.2%
9. UBS AG 0.8%
10. Custody Bank of Japan, Ltd. (Trust Account) 0.7%

Activist Activity

Hikari Tsushin K.K. 40.65%

2026-01-09 · change

NBSE Inc. 6.09%

2025-11-04 · change

ORIX CORPORATION 4.67%

2025-10-09 · correction

ORIX CORPORATION 4.67%

2025-10-03 · initial_5pct

NBSE Inc. 6.19%

2025-09-02 · correction

Historical Per-Share Data & Valuation Ratios

Per Share Metric	FY 2023	FY 2024
Revenues per share	¥794	¥998
FCF/Share	¥238	¥-478
EPS	¥79	¥181
DPS	¥0	¥27
Capital Spending per share	¥2	¥3
Book Value per share	¥580	¥753
Common Shares Outstanding	11M	11M

Financial Aggregates & Margins

Financial Aggregate	FY 2023	FY 2024
Revenues (Net Sales)	¥9B	¥11B
Operating Margin (%)	15.7%	17.4%
Net Profit (owners)	¥1B	¥2B
Net Profit Margin (%)	10.0%	18.2%
Working Capital	¥2B	¥3B
Total Debt (Interest-bearing)	¥5B	¥0B
Net Worth (Common Equity)	¥6B	¥8B
Return on Total Assets (ROA)	3.8%	16.7%
Return on Common Equity (ROE)	13.7%	24.1%

Business Summary & Analysis

Capital Strategy Targets

No active capital policy disclosure records found.